Panobinostat
Top View
- Physiologically-Based Pharmacokinetic Model Predictions of Panobinostat (LBH589) As a Victim and Perpetrator of Drug-Drug Interactions
- Development of a Human in Vitro Blood–Brain Tumor Barrier Model Of
- Table S1. Recent Registered Clinical Trials on Phenolic Compounds with Epigenetic Mechanisms in Different Cancers Alone and in Co-Treatment
- Panobinostat (Farydak®) EOCCO POLICY
- Emerging Drugs for Prostate Cancer
- Panobinostat (Farydak®) Pronounced: “Pan‐Oh‐BIN‐Oh‐Stat”
- Chemogenomic Screening Identifies the Hsp70 Co-Chaperone HDJ2 As
- Pomalidomide and Dexamethasone Combination with Additional
- NINLARO® (Ixazomib) Oral Capsule
- HDACI): in Vitro and in Vivo Studies in Thyroid Cancer
- The Synergistic Effect of DZ‑NEP, Panobinostat and Temozolomide Reduces Clonogenicity and Induces Apoptosis in Glioblastoma Cells
- Leukemia Insights Spring 2011
- Computationally Predicting Clinical Drug Combination Efficacy With
- Recommendations for Patients with Relapsed/Refractory Disease1
- Integration of Novel Agents Into the Care of Patients with Multiple Myeloma
- State and Specialty Pharmacy Drug Reimbursement Rates
- HDAC Inhibitors Elicit Metabolic Reprogramming by Targeting Super-Enhancers in Glioblastoma Models
- FARYDAK Safely and Effectively